[1] |
Kapoor A, Lanctot KL, Bayley M, et al. Screening for post-stroke depression and cognitive impairment at baseline predicts long-term patient-centered outcomes after stroke[J]. J Geriatr Psychiatry Neurol, 2019, 32(1): 40-48.
|
[2] |
Zetterberg H, Skillbäck T, Mattsson N, et al. Association of cerebrospinal fluid neurofilament light concentration with alzheimer disease progression[J]. JAMA Neurol, 2016, 73(1): 60-67.
|
[3] |
Olsson B, Portelius E, Cullen NC, et al. Association of cerebrospinal fluid neurofilament light protein levels with cognition in patients with dementia, motor neuron disease, and movement disorders[J]. JAMA Neurol, 2019, 76(3): 318-325.
|
[4] |
中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南2018[J]. 中华神经科杂志, 2018, 51(9): 666-682.
|
[5] |
Marques TM, van Rumund A, Oeckl P, et al. Serum NFL discriminates parkinson disease from atypical parkinsonisms[J]. Neurology, 2019, 92(13): e1479-e1486.
|
[6] |
Li J, You SJ, Xu YN, et al. Cognitive impairment and sleep disturbances after minor ischemic stroke[J]. Sleep Breath, 2019, 23(2): 455-462.
|
[7] |
Malojcic B, Giannakopoulos P, Sorond FA, et al. Ultrasound and dynamic functional imaging in vascular cognitive impairment and Alzheimer’s disease[J]. BMC Med, 2017, 15(1): 27.
|
[8] |
邹永明,田志岩,张惠红, 等. 不同类型痴呆患者阿尔茨海默病相关神经丝蛋白水平和嗅觉功能差异的比较[J]. 中华老年医学杂志, 2018, 37(7): 738-742.
|
[9] |
Pereira JB, Westman E, Hansson O, et al. Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer’s disease[J]. Neurobiol Aging, 2017, 58: 14-29.
|
[10] |
Gaetani L, Blennow K, Calabresi P, et al. Neurofilament light chain as a biomarker in neurological disorders[J]. J Neurol Neurosurg Psychiatry, 2019, 90(8): 870-881.
|
[11] |
彭丽君,钱海蓉,毛琳玲, 等. 神经丝蛋白轻链在视神经脊髓炎谱系疾病诊断和预后中的意义[J]. 中华神经科杂志, 2017, 50(6): 430-434.
|
[12] |
Mattsson N, Cullen NC, Andreasson U, et al. Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease[J]. JAMA Neurol, 2019, 76(7): 791-799.
|
[13] |
van der Ende EL, Meeter LH, Poos JM, et al. Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study[J]. Lancet Neurol, 2019, 18(12): 1103-1111.
|
[14] |
Novakova L, Zetterberg H, Sundström P, et al. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein[J]. Neurology, 2017, 89(22): 2230-2237.
|
[15] |
Byrne LM, Rodrigues FB, Blennow K, et al. Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington’s disease: a retrospective cohort analysis[J]. Lancet Neurol, 2017, 16(8): 601-609.
|
[16] |
Weston PSJ, Poole T, Ryan NS, et al. Serum neurofilament light in familial Alzheimer disease: a marker of early neurodegeneration[J]. Neurology, 2017, 89(21): 2167-2175.
|
[17] |
Gattringer T, Pinter D, Enzinger C, et al. Serum neurofilament light is sensitive to active cerebral small vessel disease[J]. Neurology, 2017, 89(20): 2108-2114.
|
[18] |
Levine DA, Wadley VG, Langa KM, et al. Risk factors for poststroke cognitive decline: the REGARDS study (reasons for geographic and racial differences in stroke)[J]. Stroke, 2018, 49(4): 987-994.
|
[19] |
Liang Y, Chen YK, Liu YL, et al. Cerebral small vessel disease burden is associated with accelerated poststroke cognitive decline: a 1-year follow-up study[J]. J Geriatr Psychiatry Neurol, 2019, 32(6): 336-343.
|